(MedPage Today) — DENVER — The combination injectable cabotegravir-rilpivirine (CAB-RPV; Cabenuva) safely maintained long-term viral suppression among adolescents with HIV who switched from daily oral medications, according to a multinational…
Source link : https://www.medpagetoday.com/meetingcoverage/croi/120059
Author :
Publish date : 2026-02-26 18:16:00
Copyright for syndicated content belongs to the linked Source.
